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ABSTRACT 
 
Stavudine (d4T), a nucleoside reverse transcriptase inhibitor (NRTI) used to treat 
infection by the human immunodeficiency virus (HIV), is associated with the 
development of peripheral neuropathy and pain in HIV-positive patients. The 
mechanisms of this toxic neuropathy are poorly understood, primarily due to a 
lack of relevant animal models of the neuropathological process initiated by d4T. I 
investigated whether daily oral or subcutaneous administration of d4T produces 
neuropathological changes. Compared to previous descriptions of mechanical 
hypersensitivity induced by daily oral administration of d4T to rats at a dose of 50 
mg.kg
-1
over a four week period, I found that this dosing regimen did not result in 
hyperalgesia to blunt and punctuate mechanical stimuli applied to the 
gastrocnemeus muscle. In agreement with the lack of hyperalgesia, oral 
administration of d4T at 50 mg.kg
-1 
over a four week period did not induce 
significant myelinated nerve fibre loss or morphological changes in the sciatic 
nerve. I then investigated whether administering 100 mg.kg
-1 
d4T subcutaneously, 
and therefore avoiding first-pass metabolism, to rats for four weeks causes 
hyperalgesia and neuropathological changes in nerve morphology. Daily 
subcutaneous injections of d4T at 100 mg.kg
-1 
over a four week period did not 
induce the development of hyperalgesia to a punctate mechanical stimulus applied 
to the tail or significant neuropathology. My studies demonstrate that multiple 
administrations of d4T at 50 mg.kg
-1 
orally or 100 mg.kg
-1 
subcutaneously over a 
four week period do not induce hyperalgesia or nerve fibre pathology in rats. 
iv 
 
Thus, developing a robust animal model of d4T-induced neuropathy may be 
challenging in the absence of HIV-infection, such that occurs in infected patients.  
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Introduction 
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HIV-associated Sensory Neuropathy (HIV-SN) is the most common cause of 
peripheral neurological dysfunction in HIV, and is characterized by distal axonal 
degeneration (Woolff et al., 2004; Pardo et al.,2001; Polydefkis et al., 2002; Zhou 
et al., 2007), where there is a loss of small unmyelinated fibres, which is followed 
by a loss of large myelinated fibres in more advanced cases (Cherry et al., 2003).. 
This nerve fibre degeneration is accompanied by the release of local inflammatory 
mediators, which enhances the sensitivity of surrounding, uninjured fibres, 
contributing to neuropathic pain (Keswani et al., 2002). Furthermore, the regrowth 
of damaged nerve fibres appears to be impaired with HIV infection (Hahn et al., 
2007) and regeneration of injured nerve fibres is rare (McArthur et al., 2005) and 
regeneration of injured nerve fibres is rare (McArthur et al., 2005). 
 
About 50% of individuals infected with the human immunodeficiency virus (HIV) 
develop HIV-associated sensory neuropathy (HIV-SN), a peripheral sensory 
neuropathy that is often painful, and is characterised by length-dependent 
degeneration of myelinated and unmyelinated nerve fibres (Keswani, et al., 2002; 
Ferrari et al., 2006). Non-painful peripheral neuropathy may be the result of 
partial damage to the nervous system and limited C-fibre dysfunction, allowing 
for normal nociception (Keswani et al., 2002).  
 
HIV-SN is divided into two clinically indistinguishable sub-categories, namely 
HIV-associated distal sensory neuropathy (HIV-DSP) and antiretroviral toxic 
neuropathy (ATN), depending on the onset of signs and symptoms relative to 
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starting antiretroviral therapy (ART) (Cornblath & Hoke., 2006; Ferrari et al., 
2006). Key signs of the neuropathy include reduced vibration sense, temperature 
thresholds, pin-prick sensitivity and deep-tendon reflexes, while key symptoms 
include pain, numbness and paraesthesias (Smyth et al., 2007, Martiz et al., 2010, 
Wadley et al., 2011). Our knowledge of how these factors damage sensory 
neurones is limited, which has impeded the development of effective therapeutic 
interventions for HIV-SN. Therefore, HIV-SN continues to be a major cause of 
disability despite the introduction of less neurotoxic treatment regimens, and 
improved virologic control (Smyth, et al., 2007). Much of what is known about 
the mechanisms of HIV-induced neuropathy and the pain associated with that 
neuropathy was discovered using animal models. The HIV envelop glycoprotein 
gp120 is associated with neurotoxic and nociception in rats (Herzberg & Sagen., 
2001; Milligan et al., 2000). HIV-gp120 induces an immune response through 
macrophage infiltration of the peripheral nerve and dorsal root ganglia (Wallace et 
al., 2007) and activates macrophage and astrocytes in the brain and spinal cord 
(Herzberg & Sagen, 2001; Wallace et al., 2007), which then release the pro-
inflammatory cytokines interleukin (IL)-1, tumour necrosis factor (TNF)-α, IL-6 
as well as nitric oxide (NO) in the spinal cord (Herzberg & Sagen,2001; Milligan 
et al., 2001; Milligan et al., 2000). NO mediates the nociceptive response of spinal 
dorsal horn neurons in hyperalgesic states induced by inflammation (Keswani et 
al., 2003b) 
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While nucleoside reverse transcriptase inhibitors (NRTIs) form an important part 
of the highly active antiretroviral therapy (HAART), the mechanisms of NRTI-
induced toxic neuropathy are still not well understood partly due to the scarcity of 
robust animal models of the disease, especially of models employing agents still 
in common use. The purpose of this introduction is to briefly describe the 
different forms of HIV-SN resulting from both HIV infection as well as NRTI 
use, and then to focus on describing animal models of NRTI-induced neuropathy 
and nociceptive hypersensitivity.  
 
1.1 Peripheral neuropathies in HIV-positive patients 
1.1.1 Pre-Highly active antiretroviral treatment (HAART) era: 
The incidence of HIV-DSP increases with the disease progression, from very low 
rates during the early stages of infection (1-2%), to high rates at end-stage disease 
(~35%) (Barohn et al., 1993, So et al., 1988). In the majority of patients 
developing HIV-DSP, the neuropathy is symptomatic, with numbness and pain 
being the most common symptoms (Fuller et al., 1993, Tagliati et al., 1999). The 
prevalence of HIV-DSP in ambulatory HIV-positive individuals, who are not on 
antiretroviral therapy, and who are attending outpatient clinics is around 14% 
(Forna et al., 2007).  
 
The polyneuropathy that developed in the Pre-HAART era, and continues to 
develop in individuals without access to HAART, is thought to result from 
immune dysfunction within the nervous tissue, which leads to inappropriate 
release of inflammatory mediators that can be neurotoxic (Kamerman et al., 
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2011). These inflammatory mediators increase the sensitivity of surrounding 
uninjured fibres, thus contributing to neuropathic pain (Keswani et al., 2002). 
Experimental evidence supporting this mechanism of action includes recent 
studies by Laast et al (2007), who infected macaque monkeys with simian 
immunodeficiency virus (SIV), which resulted in neuronal loss in the trigeminal 
nerve ganglia of the monkeys and reduced conduction velocity in C-fibres, and 
Zhu et al (2007), who infected cats with feline immunodeficiency virus (FIV), 
which was associated with reduced axonal density and dying-back of distal nerve 
fibre endings in the sural nerve. 
 
1.1.2 HAART era: 
The Highly active antiretroviral therapy (HAART) is currently the most effective 
treatment for acquired immunodeficiency syndrome (AIDS), and has resulted in 
increased patient survival (Dorsey et al., 2009).  HAART works by reducing viral 
load and increasing the CD4 T-cell count, and therefore it was expected that it 
would reduce the incidence of HIV-SN when it was introduced. But, the 
prevalence of HIV-SN has not decreased with the introduction of HAART. 
Indeed, the rate may have increased, with recent reports describing prevalences 
close to 60% (Wadley et al., 2011; Maritz et al., 2010). The reason for the 
continued high rate of HIV-SN is the neurotoxicity of some classes of NRTIs for 
example zalcitabine (ddC), didanosine (ddI) and stavudine (d4T) (Dalakas, 2001). 
Of all the NRTIs, Zidovudine (AZT) is the only drug which hasn’t been 
implicated as a neurotoxin (Dalakas, 2001). It became clear early after the 
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introduction of NRTIs that they were neurotoxic, with ddC being the most 
neurotoxic. For example, monotherapy with ddC alone caused toxic neuropathy 
within seven to nine weeks of starting treatment in 100% of patients administered 
a high dose (≥ 0.12 mg.kg-1 per day) of the drug (Berger et al., 1993). Whereas a 
very high dose of ddI (≥ 12mg.kg-1 per day), resulted in neuropathy in 
approximately 50 % of patients (Lambert et al., 1990). Also, the toxicity of the 
drugs appears to be additive, such that the incidence of ATN is increased when 
NRTIs are used in combination. The dual administration of ddI and d4T was 
associated with a 3.5-fold risk of sensory neuropathy compared with ddI alone and 
a 2.5-fold risk compared to d4T, and therefore more neurotoxic than ddI or d4T 
alone (Moore et al., 2000).  
 
Early studies on d4T, using d4T doses similar to therapeutic doses, reported that 
after one year of d4T use, 12-15% of the subjects had developed peripheral 
neuropathy, with those with the greatest level of immunosuppression individuals 
being at the greatest risk (Simpson et al., 1995). More recently our laboratory 
showed that 21% of patients d4T-based HAART developed ATN within three 
months of initiating therapy, and 41% had developed ATN by six months 
(Kamerman, personal communication). And, Winston and colleagues (2005) 
conducted a study in which 6% of HIV-negative individuals taking the 28-day 
d4T course (post-exposure prophylaxis) developed symptoms of HIV neuropathy, 
illustrating that even in healthy individuals, d4T is neurotoxic, although at a 
reduced level. 
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The continuing problem of HIV-SN is highlighted in a study by Smyth and 
Colleagues (2007). They conducted a study in which they described the 
prevalence and risk factors for HIV-SN both in the pre-HAART (1993) and 
HAART (2001) eras, and reported that the prevalence of this neuropathy 
increased from 13% in the pre-HAART era to 44% in the HAART era.  
Although NRTIs are effective in suppressing HIV-1 RNA levels and increasing 
CD4 cell counts, they have a potential of decreasing a patients quality of life if 
they cause symptomatic neuropathy (Simpson et al., 2003).  
 
Most researchers believe that the toxic effects of antiretroviral drugs, in HIV-
positive patients, unmasks and enhances previously existing distal sensory 
polyneuropathy caused by the virus (Keswani et al., 2002). The virus, pro-
inflammatory cytokines and chemokines are thought to cause the initial peripheral 
nerve injury, which then is exacerbated by the toxic effects of antiretroviral drugs, 
resulting in symptomatic, painful neuropathy (Keswani et al., 2002).  The 
association between the symptomatic development of neuropathy and the start of 
antiretroviral therapy currently is necessary for the diagnosis of NRTI-induced 
neuropathy, as the clinical signs and symptoms of NRTI related neuropathy are 
similar to those of HIV-DSP (Cornblath et al., 2006), but the pattern of this 
neuropathy is different to the slowly progressive HIV-DSP in that there is a 
sudden onset of signs and symptoms, typically intense burning discomfort in both 
feet after six to eight weeks of treatment (Husstedt et al., 2001). The signs include 
impaired temperature and vibratory sensation, while cramps and pains (typically 
burning in quality) in the feet and legs (Simpson & Tagliati, 1995). Kokotis and 
colleagues (2007) showed that, although the clinical symptoms of both kinds of 
neuropathy are the same, the pathology of toxic neuropathy and distal sensory 
polyneuropathy may differ. The researchers found that neuropathy caused by the 
virus was associated largely with a decrease in the conduction velocity of 
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myelinated nerve fibres, while toxic neuropathy appeared to decrease the 
conduction velocity mainly of unmyelinated fibres.  
 
The following guidelines were developed to assist differentiating HIV-DSP from 
ATN, with affirmative answers to any of the questions indicating ATN is likely: 
1. Is there is clinical or electrophysiological improvement of symptoms after 
stopping therapy (NRTI) 
2. Is there an association between the onset of symptoms or rapid worsening 
of  neuropathic symptoms after initiating NRTI therapy 
3. Is there worsening of neuropathic symptoms after discontinuation of NRTI 
therapy, followed by clinical improvement of symptoms later on. 
(Dalakas, 2001).  
 
The neurotoxic side effects of NRTIs are thought to be related to their disruption 
of mitochondrial function (Kakuda, 2000). NRTIs are derivatives of adenosine, 
cytidine, guanosine and thymidine, which provide an alternative substrate for 
DNA polymerases terminating DNA synthesis (Kakuda, 2000). While the drugs 
target viral DNA polymerase, human DNA polymerase gamma (γ), which 
transcribes mitochondrial DNA, is also sensitive to the inhibiting effects of the 
drugs, resulting in impaired mitochondrial DNA synthesis, and ultimately 
impaired mitochondrial function through failure of the electronic transport chain 
(Kakuda., 2000).  
 
Given the continued high use of d4T in developing countries, even those like 
South Africa where the drug is no longer prescribed as first-line therapy, it is 
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expected that HIV-SN will continue to affect the HIV-positive patients for some 
time to come. Thus, it is important that treatments be developed, but in order to do 
that we need good animal models of the drug-induced disease processes causing 
the neuropathy so therapeutic targets can be identified. For the remainder of the 
introduction chapter, I will be covering what is known about animal models of 
NRTI-induced hypernociception and neurotoxicity.  
 
1.2 Models of NRTI-induced pain and neurotoxicity:  
1.2.1 Animal models for HIV/ NRTI-induced pain 
In an animal study examining pain caused by antiretroviral drugs, Joseph and 
colleagues (2004) developed a model of painful peripheral neuropathy induced by 
NRTI, wherein they showed that didanosine (ddI), zalcitabine (ddC) and 
stavudine (d4T) produced dose-dependent mechanical hypersensitivity as well as 
allodynia when administered to rats. In their study, a single intravenous injection 
of the NRTIs ddI, ddC and d4T to rats resulted in a dose-dependent mechanical 
and thermal hyperalgesia of the hind paw that lasted for twenty days. 
Hyperalgesia was observed with all of these NRTIs within one day when a dose of  
50 mg.kg
-1
 was used, and within three days with the 25 mg.kg
-1
 and 10 mg.kg
-1
 
doses.  
 
Although studies on diabetic and chemotherapy-induced neuropathy have shown 
these neuropathies are mediated, in part, by second messengers such as protein 
kinase A, nitric oxide synthase, protein kinase G, and mitogen activated protein 
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kinase  in the peripheral terminals of afferent nociceptors (Aley & Levine, 1999), 
the hypersensitivity elicited by ddC injections was not diminished by inhibitors to 
any of these second messengers (Joseph et al, 2004). However, drugs which 
buffered intracellular calcium diminish ddC-induced mechanical hypersensitivity 
when administered both peripherally and centrally, leading the authors to suggest 
that altered calcium signaling played a role in the development of NRTI-induced 
hypersensitivity and that calcium homeostasis was impaired by mitochondrial 
dysfunction caused by NRTIs (Joseph et al., 2004). 
 
But in subsequent studies, Joseph and Levine (2006) showed that disrupting the 
mitochondrial electron transport chain and preventing mitochondrial 
phosphorylation, attenuated ddC induced hyperalgesia and allodynia, a finding 
that is not in agreement with the proposed mechanism of action of NRTIs, which 
assumes that NRTIs cause inhibition of mitochondrial DNA synthesis and a 
subsequent decrease in the production of mitochondrial proteins, which results in 
a decrease in mitochondrial energy production. Therefore drugs that block the 
mitochondrial electron transport chain might be expected to exacerbate the effects 
of NRTIs and potentially enhance the hyperalgesia caused by NRTIs, instead of 
abolishing NRTI-induced hyperalgesia as shown by Joseph and Levine (2006).   
 
In another model of ATN-induced neuropathic pain developed around a single 
injection of an NRTI, Bhangoo and colleagues (2007) demonstrated the 
involvement of CXCR4 in neuropathic pain signaling. In this study, a single 
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intraperitoneal (i.p) injection of ddC was administered to rats and increased levels 
of CXCR4 mRNA expression were observed in glial cells of the dorsal root 
ganglion and peripheral nerves following drug administration. Furthermore, this 
ddC-induced mechanical hypersensitivity was alleviated by CXCR4 antagonist, 
thus implicating CXCR4 involvement in the development of the hypernociception 
(Bhangoo et al., 2007). Interestingly, the changes in hypersensitivity correlated 
with nerve pathology. Bhangoo and colleagues (2007) sectioned sciatic nerve 
samples for histological assessment and nerve pathology was observed within 
three days following a single i.p injection of ddC and consisted of hypertrophy of 
the myelin sheath and tormaculae (Figure 1). 
 
 
Figure 1. Nerve morphology of the sciatic nerves obtained from a vehicle-treated 
rat (A) and a rat administered a single i.p injection of ddC (B). From the figure we 
note the formation of tomaculae in ddC treated rat, hypertrophy of the myelin 
sheath resulting in the formation of myelin loop (Bhangoo et al., 2007). 
 
B 
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In contrast to the findings of Bhangoo and colleagues (2007) study, others have 
found no significant effect of ddC injection on nerve morphology. For example 
Siau et al. (2006) found that a single injection of ddC into the tail vein of rats had 
no effect on intraepidermal nerve fibre density, a measure of axonal die-back that 
is a characteristic feature of the neuronal damage observed in humans with HIV-
SN, in the hind paw. Systemic injections of ddC three times a week for three 
weeks did however decrease epidermal nerve fibre density in the lateral plantar 
surface of the hind paw of rats (Wallace et al., 2007b). Thus, it appears that a 
single intravenous (i.v) injection of ddC may cause morphological changes in 
peripheral neurones and may result in an increased sensitivity to noxious 
stimulation, but that a reduction in peripheral nerve fibre density occurs only with 
continuous NRTI administration.  
All the models I have described so far have involved parenteral routes of drug 
administration and all used ddC. I will now discuss models employing oral routes 
of drug administration, and studies involving d4T and ddI, the two drugs that, 
until recently, were still used clinically to treat HIV-infection as first or second-
line regimens.  
 
In one of the first studies to employ oral administration of ddC, Anderson and 
colleagues (1992) found that chronic oral administration of ddC induced a 
decrease in conduction velocity in the distal sural nerve and structural damage in 
28 the sciatic nerve of rabbits. Evidence of neuronal pathology was observed in 
dorsal root ganglia, the peripheral sensory system, the ventral roots and the 
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peripheral motor system, and was typified by myelin splitting, intramyelin edema, 
demyelination and remyelination of axons, and axonal loss. Also, Feldman and 
colleagues (1992) observed changes in the sciatic nerve and ventral roots structure 
induced by ddC, typically separation of myelin lamellae, fragmentation of myelin 
sheaths, demyelinated and remyelinated axons. In a more recent study, Joseph and 
colleagues (2004) administration ddC orally to rats at a dose of 50 mg.kg
-1 
daily 
for six weeks; which resulted in mechanical and thermal hyperalgesia in the hind 
paw from seven days onward. However, a lower dose of 25 mg.kg
-1
 of ddC 
induced hyperalgesia only after three weeks of daily oral administration. Thus, a 
in contrast to the rapid onset of hyperalgesia with i.v administration, and high oral 
bioavailability of NRTIs (Kaul et al., 1999; Kelley et al., 1987), the occurrence of 
hyperalgesia and allodynia was only evident after one week of daily oral 
administration of 50 mg.kg
-1 
ddC to rats (Joseph et al., 2004); indicating that the 
route of administration has significant effect on toxicology, with the oral route 
having less toxicity. Unfortunately, Joseph and colleagues did not confirm 
whether the hyperalgesia they measured after administering ddC orally was 
associated with nerve pathology.  
 
While the evidence supporting and algogenic and in vivo neurotoxicity of ddC is 
good, the evidence for in vivo toxicity of d4T and ddI in animals other than 
humans is poor. Warner and colleagues (1995) failed to observe signs of 
peripheral neurotoxicity in rabbits given oral ddI or d4T once daily for 24 weeks. 
In their model, the rabbits were administered doses of the drug far in excess of the 
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therapeutic doses used in humans (ddI: 250 or 400 mg.kg
-1  
per day depending on 
body mass; d4T: 30 mg
 
or 40 mg
  
twice daily depending on body mass; WHO, 
2004). Yet, even these high doses of ddI and d4T, the drugs failed to induce 
significant changes in the peripheral nervous system and no change in peripheral 
nerve conduction or in the histopathology of peripheral or central nerves 
indicative of neuropathy (Warner et al., 1995). However, when Schmued et al 
(1996) administered ddI orally, twice daily, for 20 weeks, and observed 
morphological changes to neurones in the sciatic nerve identical to those 
described following ddC administration to rabbits (Feldman et al., 1992). For 
example, the nerve fibres were swollen, while the myelin was split into two 
distinct sheaths. Pattersons’ group (2000) also reported similar observations, 
which were evident after 15 weeks of daily ddI administration (415 mg.kg
-1
 twice 
daily), while abnormal nerve fibre morphology was less frequent and only 
observed after 20 weeks. The authors suggested that the nerves may have been 
able to adapt to the toxic effects of ddI, making partial recovery during drug 
administration possible (Patterson et al., 2000), resulting in the improvement in 
nerve fibre morphology observed after 20 weeks. 
 
Only one model employing oral administration of d4T has been described where 
Weber et al (2007) developed a rat model of d4T induced hyperalgesia by daily 
oral administration of d4T at a dose of 50 mg.kg
−1
 to rats which resulted in 
mechanical hyperalgesia, within three weeks of d4T administration, and the 
hyperalgesia persisted for up to six weeks. However, hyperalgesia to the thermal 
15 
 
challenge (49 °C water) did not develop and the overall condition of the rats was 
not affected by the d4T. Unfortunately, they did not assess for the presence of 
nerve pathology, but a lack of apoptosis and inflammatory cytokine expression in 
the dorsal horn of the spinal cord, a characteristic feature of neuropathic pain 
states, indicates that the pain may not have been neuropathic in origin (Weber et 
al., 2009). Recently, Dorsey et al (2009) developed an animal model of d4T, 
where a single 50 mg.kg
−1
 i.v injection of d4T resulted in robust tactile allodynia 
within 24hrs of d4T administration. This allodynia was associated with the 
expression of Gan1 gene in cells in the dorsal horn of the spinal cord. Changes in 
the expression of this gene has been associated with other rare forms of 
neuropathy, indicating that the allodynia may be neuropathic in origin. Thus, it is 
unclear whether hypernociception caused by d4T in rodents is neuropathic or not.   
 
The inconsistencies in the effects of NRTIs have on nerve fibres and pain in 
animal models may be caused by the difference in the toxicity of the NRTIs 
tested, the duration of NRTI exposure, and the different nociceptive testing 
methods used. It could also be due to the different routes of administration, as 
well as by the animal species used. Consequently, the mechanisms of ATN remain 
poorly understood due to lack of robust and relevant animal models.  
 
1.3 Aims of the Dissertation 
 
Until recently, In South Africa, there were two HIV treatment regimens for both 
adults and childrens wherein regimen 1 for adults includes d4T and regimen 2 for 
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children includes ddI: which are both associated with ATN neuropathy (SA HIV 
treatment guidelines, 2010).  Also, antiretroviral treatment is often initiated in 
patients with a weakened immune system i.e. CD4 T-cell count <200cells.mm
3
 
irrespective of clinical stage or CD4 count <350cells.mm
3
 in patients with TB & 
HIV and in pregnant women (SA ART treatment guidelines, 2010). Initiating 
antiretroviral therapy at advanced stages of HIV infection increases the risk of 
developing ATN neuropathy.  
In 2010, the use of d4T and ddI in patients initiating antiretroviral therapy (ART) 
was stopped (DOH HIV treatment guidelines, 2010). However, the bulk of 
existing patients remain being treated with these drugs, especially d4T, and often 
they develop painful HIV-SN. Our understanding of this drug-induced 
neuropathy, and therefore the treatment of the condition, is compromised due to 
very few d4T animal models of this neuropathy with which to study the disease 
process. In our laboratory, Weber and colleagues (2007, 2009) developed a model 
of NRTI induced mechanical hypersensitivity by administering d4T orally to rats 
However, they provided no evidence that the hyperalgesia that developed was the 
result of peripheral nerve damage. Therefore the aims of this dissertation are to 
develop a robust animal model of stavudine-induced hyperalgesia: 
 By looking at the effects of administering d4T via two routes and 
monitoring the changes in nerve morphology of the sciatic and cocxygeal 
nerves.  
 by looking at the effects of administering d4T via two routes and 
monitoring the development of hyperalgesia 
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CHAPTER 2 
 
 
 
 
General methods 
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2.1 Animals 
The methods described in this chapter are those methods that are common to 
experiment 1 (chapter 3) and experiment 2 (chapter 4). A description of the study 
specific experimental designs for experiment 1 and experiment 2 are given in 
chapters 3 and 4, respectively. 
 
I used a total of 55 Sprague-Dawley (200-250)g rats. All rats were housed at an 
air temperature of ~23°C on a 12:12 h light/dark cycle (lights on at 07h00), with 
access to food and water ad libitum. In Experiment 1: Oral d4T (Chapter 3), rats 
were housed individually in cages to ensure that the each animal received the 
correct mass-specific dose of drug administered in a gelatine cube placed in their 
cage. In Experiment 2: Subcutaneous d4T (Chapter 4), rats were housed in pairs 
because drug delivery was entirely under the control of the experimenter. All 
experimental procedures were approved by the Animal Ethics Screening 
Committee of the University of the Witwatersrand, South Africa AESC: 
2006/24/03 and AESC: 2007/06/03. 
 
2.2 Nerve histology  
 
Segments of sciatic (Experiment 1: Oral d4T) and coccxygeal nerves (Experiment 
2: Subcutaneous d4T) dissected from anaesthetized rats were immersed in 2% 
parafomaldehyde and 2% glutaraldehyde in 0.1M phosphate buffer (pH 7.4) for 
24 hours. Then the tissue was rinsed in phosphate buffer (pH 7.4) and osmicated 
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in 0.1M phosphate buffer with 2% osmium tetroxide. The tissue was then 
dehydrated through graded alcohols and embedded in resin. Thereafter, 0.5m 
semithin sections of nerves were cut and stained with toloudine blue dye for 
examination using light microscopy. Nerve sections were photographed at 40X 
magnification, and two 100 X 100 µm
2
 areas per section were printed on 15.6 cm 
x 16.3 cm (80 g.m
-2
)
 
white paper, and analyzed for nerve pathology using the 
method described by Flatters (2008). In each of the 100 X 100 µm
2
 sections, I 
counted the number of myelinated axons as well as the number of healthy 
myelinated axons with signs of pathology. The pathological features I assessed 
were: splitting, balooning and infolding of the myelin sheath. The values recorded 
from the two 100 X 100 µm
2
 sections from each nerve were then averaged, and 
the averaged values were then used in all data analysis. Thereafter, I determined 
the cross-sectional area of the myelinated fibres, and the cross-sectional area of 
their axoplasm and myelin sheath, by cutting out the respective structures from the 
printed sheets, and calculating the cross-sectional areas according to the following 
formula: 
weight of paper cut-outs (g)       X      10 000 µm
2
 
weight of 254 cm
2
  paper sheet (g)          
  
2.3 Behavioral nociceptive tests 
 
I assessed withdrawal response thresholds to punctate and blunt mechanical 
stimuli applied to the gastrocnemius muscle (Experiment 1: Oral d4T), and a 
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punctate stimulus applied to the mid-region on the dorsal aspect of the tail 
(Experiment 2: Subcutaneous d4T). The punctate stimulus was applied using an 
electronic von Frey anaesthesiometer (ITTC, Life Sciences, USA), and the blunt 
stimulus was applied using a somedic analgesiometer (Somedic, AB, Horby, 
Sweden) with a 0.5 mm diameter rubber probe. The stimuli were applied until 
limb or tail withdrawal (escape behavior) was elicited, and the average of three 
measurements, taken one minute apart, was recorded as the withdrawal threshold. 
When applying the punctuate and blunt stimuli to the gastrocnemius muscle 
(Experiment 1: Oral d4T), a handler placed a light cloth over the rat and gently 
restrained the animals body by hand, while the experimenter held the animal’s leg 
and applied the stimulus to the leg (Loram et al., 2007a). When applying the 
punctate stimulus to the tail (Experiment 2: Subcutaneous d4T), animals were 
restrained in clear plastic restrainers that restricted body movement but allowed 
free movement of the tail (Loram et al., 2007b). Animals were habituated to the 
appropriate method of restraint daily for a week prior to commencing 
experiments. 
 
2.4 Data analysis 
All data are expressed as mean (SD). Changes in withdrawal thresholds over time 
were described by fitting regression lines to the data When the same type of 
equation (e.g. linear equation) could be used to describe changes in withdrawal 
thresholds over time in the control and experimental groups (Experiment 1: Oral 
d4T), withdrawal thresholds between the two groups were assessed by comparing 
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the regression line coefficients, intercepts and slopes. When different regression 
equations were used to describe the changes in withdrawal thresholds between the 
two groups (Experiment 2: Subcutaneous d4T) then student’s t-tests were used.  
Comparisons of the number of myelinated axons, the number of abnormal axons, 
and myelin and axoplasm area of myelinated fibres in sciatic nerve and 
coccxygeal nerve sections were analyzed using one-way ANOVA. The threshold 
for statistical significance was set at P<0.05. 
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CHAPTER 3 
 
 
 
 
 
 
 
Experiment 1: Oral administration 
of d4T 
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3.1 Introduction 
Painful peripheral neuropathy continues to be a debilitating side-effect of NRTIs 
(Kamerman et al., 2012) and this pain is largely unresponsive to current 
pharmacological treatments for neuropathic pain (Phillips et al., 2010). Until 
recently in South Africa, the first-line HIV treatment regimen for adults and 
second-line treatment regimen for children included d4T and ddI respectively 
(DOH HIV treatment guidelines, 2010). The guidelines have now been amended 
such that new patients starting therapy do not start on d4T or ddI base regimens. 
However, the majority of existing patients who are on therapy remain treated with 
these drugs, especially d4T. Thus, the potential burden of iatrogenic painful 
peripheral neuropathy remains high. In a recent study looking at the prevalence of 
HIV-SN in South Africans, Maritz and colleagues (2010) reported the prevalence 
of the  neuropathy  was 49% in their study population, and 30% of those were 
diagnosed with painful neuropathy. The mechanisms underlying the NRTI-
induced neuropathies are still unclear and better understanding of these 
neuropathies will facilitate development of effective treatment for these painful 
neuropathies.  
 
In our laboratory, Weber and colleagues (2007, 2009) developed a model of NRTI 
induced mechanical hypersensitivity by administering d4T orally to rats over a six 
week period. In this study, they found that rats developed hyperalgesia within 
three week of drug administration and the hyperalgesia remained constant over the 
remaining three weeks of drug administration (Weber et al., 2007). However, 
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Weber et al (2007) provided no evidence that the hyperalgesia that developed to 
orally administered d4T was the result of peripheral nerve damage.  
 
However, others have shown that hypernociception following acute (Bhangoo et 
al., 2007) and chronic (Wallace et al., 2007a) exposure to ddC is associated with 
nerve pathology. Therefore the aim of this experiment was to determine whether 
administering d4T orally to rats for four weeks causes pathological changes in 
nerve morphology. Although I administered the same dose of d4T, and followed 
the same dosing schedule, used by Weber et al (2007, 2009), I assessed 
mechanical hypersensitivity in the hind leg rather than the tail because the sciatic 
nerve that innervates the hind limb is a larger, more easily accessible nerve than 
the coccxygeal nerve that innervates the tail, and the nerve pathology described by 
Bhangoo et al 2007 in response to a single i.p dose of ddC was assessed in the 
sciatic nerve. 
 
3.2 Methods 
The animal husbandry, nociceptive testing techniques, nerve processing, and data 
analyses used in this experiment are described in Chapter 2. 
                                                                                                                       
Experimental procedures 
In the first part of this experiment, 20 rats were randomly allocated to one of two 
groups; 10 rats were allocated to the control group and 10 rats to the d4T group. 
Animals were familiarized with the handling procedures used during nociceptive 
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testing for a week before the start of nociceptive testing. During this 
familiarization time, animals also were trained to eat standard gelatine cubes, 
which contained no drug, once daily at 14h00 until they ate the entire cube within 
15 minutes. After this training period, baseline behavioral nociceptive 
measurements were made daily for five consecutive days, with all rats continuing 
to receive standard gelatine cubes containing no drug daily. On day six, animals in 
the d4T group started receiving gelatine cubes containing 50 mg.kg
-1
 d4T daily for 
four weeks, while animals in the control group continued to receive gelatine cubes 
with no added drug daily for four weeks. During this phase of the experiment, 
behavioral measurements were made once weekly over the four-week period.  
 
In the second part of this study, an additional 15 Sprague-Dawley rats (200-250)g 
were allocated to one of three groups, where rats in two of the groups were 
administered either standard gelatine cubes containing no drug (n=5) or  
50 mg.kg
-1
 d4T orally in gelatine cubes for four weeks (n=5), and animals in the 
third group received no treatment (n=5). At the end of the four week period, rats 
were anaesthetized with a mixture of 100 mg/ml ketamine (Anaket-V; Bayer 
Animal Health Pty Ltd, Isando, South Africa) and 20 mg/ml xylazine (Chanazine; 
Bayer Animal Health Pty Ltd, Isando, South Africa) at a ratio of 1:4 injected 
intramuscularly at a dose of 0.1 ml per 100 g body mass, and the sciatic nerve was 
dissected free of the surrounding tissue. Ten millimeter section, from immediately 
proximal to the trifurcation of the nerve trunk was excised and placed in fixing 
solution. Thereafter animals were administered a lethal overdose of the 
26 
 
anaesthetic. No behavioral measurements were made on these animals, but they 
were age and weight-matched to animals that were undergoing behavioral testing. 
 
Drugs and method of administration 
2’,3’-didehydro-3’-deoxythymidine (d4T, Cipla Life Sciences, South Africa) was 
prepared and administered as described by Weber et al (2007, 2009). Briefly, d4T 
(50 mg.kg
-1
) was administered once daily as a suspension in flavoured gelatine 
cubes. The gelatine cubes were prepared by dissolving 7 ml savoury bread spread 
(Bovril, Unilever, South Africa), 20 g cane sugar, and 12 g unflavoured gelatine 
powder (Davis Gelatine, Johannesburg, South Africa) in 100 ml warm water. The 
solution was aliquoted into 3 ml moulds and allowed to set. Standard cubes 
contained no drug, but d4T containing cubes were prepared by adding powdered 
d4T to the 3 ml aliquots and vortexing the aliquots before the gelatine set.  
 
3.3 Results 
Behavioural nociceptive tests 
Changes in withdrawal thresholds to a punctate mechanical stimulus over time are 
shown in Figure 2. For both groups, the change in withdrawal threshold over time 
was best described using a linear regression equation, with the withdrawal 
threshold for the control and d4T groups decreasing over the course of four weeks 
of the experiment (Control: y= 259.3-22.07x , r
2
= 0.92, p=0.009; d4T: y= 258.2-
17.68x , r
2
=0.92, p=0.008). There was no significant difference in the slope 
(Control: slope= -22.07 ± 3.63; d4T: slope= -17.68 ± 2.82) or intercept (Control: 
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intercept= 259.3 ± 8.91; d4T: intercept= 258.2 ± 6.92) of the regression lines 
between the control and d4T groups. That is, daily oral administration of d4T 
(50mg.kg
-1
) did not produce mechanical hypersensitivity to a punctate stimulus 
applied to the gastrocnemius muscle compared to rats that did not receive any 
drug.  
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Figure. 2. Mean limb withdrawal thresholds to a punctate mechanical stimulus 
measured weekly in rats before (week 0), and during (weeks 1 to 4) four weeks of 
daily oral administration of 50 mg.kg
-1
 d4T (diamonds) or drug-free (squares) 
gelatine cubes. Withdrawal threshold decreased significantly over time but there 
were no differences in withdrawal thresholds between the d4T and control groups 
over the four-week course of the experiment. 
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Figure 3 shows changes in withdrawal thresholds to a blunt mechanical stimulus. 
For both groups, the change in withdrawal threshold over time was best described 
using a linear regression equation, (Control: y= 57.42-5.55x, r
2
=0.86, Sy.x= 4.14; 
d4T: y=56.32-5.54x, r
2
= 0.78, Sy.x= 5.29). The withdrawal threshold decreased 
markedly over the course of four weeks of the experiment in both groups. 
However, there was no significant difference in the slope (Control: slope= -5.55 ± 
1.31, d4T: slope= -5.54± 1.67) or intercept (Control: intercept= 57.42 ± 3.21, d4T: 
intercept= 56.32 ± 4.10) of the regression lines between the control and d4T 
groups, showing that d4T administration did not significantly change limb 
withdrawal thresholds to a blunt mechanical stimulus. 
 
Nerve pathology 
Figure 4 shows the appearance of typical cross sections through the sciatic nerve 
of rats fed 50 mg.kg
-1 
d4T containing gelatine cubes (Figure 4A) or control 
gelatine cubes (Figure 4B) for four weeks. There was no difference in the total 
number of myelinated axons (Figure 5A, one-way ANOVA; p=0.70) or the 
percentage of abnormal axons; for example myelin splitting, oedema or infolding 
(Figure 5B, one-way ANOVA; p=0.95,) between the no intervention, the control 
and the d4T groups. Furthermore, daily oral administration of d4T did not alter 
the axoplasm area per axon (Figure 6A, one-way ANOVA; p>0.05), nor the 
myelin area per axon (Figure 6D, one-way ANOVA; p=0.76) compared to the no 
intervention and control groups. Thus, at the drug dose we used, d4T did not 
induce any significant nerve pathology in myelinated fibres. 
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Figure 3. Mean limb withdrawal thresholds to a blunt mechanical stimulus 
measured weekly in rats before (week 0), and during (weeks 1 to 4) four weeks of 
daily oral administration of 50 mg.kg
-1
 d4T (diamonds) or drug-free (squares) 
gelatine cubes. Withdrawal thresholds decreased significantly over time in both 
groups, but there was no difference in withdrawal thresholds between the d4T and 
control groups over the four-week course of the experiment. 
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Figure 4. Cross-sections of the sciatic nerve from animals administered  50 
mg.kg
-1 
d4T (A) and control (B) gelatine cubes daily for four weeks, (at 40X 
magnification). No significant myelinated axon loss or fibre pathology was 
observed in rats administered d4T. The arrows show infolding of the myelin 
sheath.  
B 
A 
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Figure 5. Mean (SD) number of myelinated axons (A) and percentage of 
abnormal myelinated axons (B) (e.g., ballooning, splitting of myelin sheath) per 
10 000 µm
2
 cross-sectional area of sciatic nerve. Administration of d4T did not 
significantly change the number of myelinated axons or the number of abnormal 
axons compared with the control and no intervention groups 
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Figure 6. Mean (SD) axopalsmic area per 10 000 µm
2
 sciatic nerve cross-section 
(A) and myelin area per 10 000 µm
2
 sciatic nerve cross-section (B). 
Administration of d4T did not alter the axoplasmic area per 10 000 µm
2
 or myelin 
area per 10 000 µm
2
 compared to the control and naive rats. 
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3.4 Discussion 
 
The aim of this experiment was to determine whether daily oral administration of 
d4T produces behavioral and neuropathological changes in the sciatic nerves of 
rats. Oral administration of d4T at 50 mg.kg
-1 
over a four week period did not 
induce hyperalgesia or significant myelinated nerve fibre loss or morphological 
changes in the sciatic nerve. My histological findings are in agreement to the 
results of Warner and colleagues (1995) who, in the only other study to 
investigate nerve and behavioral changes following d4T administration, failed to 
observe signs of peripheral neurotoxicity in rabbits administered oral d4T daily 
for 24 weeks. In their model, the rabbits were administered d4T (750 mg.kg
-1
 and 
1500 mg.kg
-1
) by gastric gavage daily for 24 weeks, and even at these high doses, 
the investigators still did not observe any mechanical hypersensitivity or 
neuropathological changes associated with the use of NRTIs.  
 
In my experiment, semi-thin sections of the sciatic nerves of rats administered 
d4T did not show changes typical of what has been reported by other investigators 
who administered other NRTIs to rats. For example, Patterson and colleagues 
(2000) were able to develop a rodent model of ddI induced myelinopathy, with 
chronic administration of very high doses of ddI (415 mg.kg
-1
, twice daily). 
However, these dose-dependant changes in myelin architecture were observed 
only after weeks 15 and 20, far beyond the duration I administered d4T. Although 
Patterson and colleagues were able to demonstrate changes which occur with 
chronic administration of NRTIs, the doses used in their study are far beyond the 
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clinically recommended doses (Schmued et al., 1996; Wientjies and Au., 1992; 
WHO guidelines, 2003).  
 
Surprisingly, daily oral administration of d4T (50 mg.kg
-1
) did not produce 
mechanical hypersensitivity to punctuate or blunt stimuli applied to the 
gastrocnemius muscle. These findings are contrary to those of Weber et al (2007) 
and Joseph et al (2004) who have both reported the presence of mechanical 
hyperalgesia following daily administration of d4T at a dose of 50 mg.kg
-1 
respectively. Joseph and colleagues (2004) administered d4T i.v, but Weber et al 
(2007) used the same dosing route I employed and the presence of hyperalgesia 
was  evident within 3 weeks of 50 mg.kg
-1 
d4T which is much sooner compared to 
the onset of painful toxic neuropathy in HIV-positive patients, occurring within 6-
8 weeks following drug administration (Husstedt et al., 2001). However, a 
noticeable difference between the original study by Weber et al (2007) tested for 
the presence of mechanical hyperalgesia in rats using using a bar algometer (a 
tonic, blunt mechanical stimulus) to the tail, whereas I applied tonic mechanical 
blunt and punctuate stimuli to the gastrocnemius muscle. The lack of 
hypersensitivity in my rats may be because of these methodological differences. 
However, if the hyperalgesia reported by Weber et al (2007& 2009) was caused 
by drug-induced nerve damage, I still would have expected to see nerve pathology 
in my rats since the dosing regimen was the same. 
 
36 
 
In conclusion, I investigated the effects of d4T on healthy rats, using a low dose of 
d4T. Based on the findings of Weber et al (2007 & 2009), my failure to detect 
changes in behavior or nerve histology could have been related to my low drug 
dose or testing behavioral nociception and histology too proximally. Therefore in 
order to study this further, I administered d4T intraperitoneally to rats and tested 
for hyperalgesia on the mid-region of the rat tail in experiment 2 (chapter 4). 
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CHAPTER 4 
 
 
 
 
 
 
 
Experiment 2: Subcutaneous 
administration of d4T 
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4.1 Introduction 
 
In our first study, I did not induce hyperalgesia or nerve pathology in rats 
administered 50 mg.kg
-1
 d4T daily orally for four weeks. This is contrary to 
Weber and colleagues’ (2007) findings that showed that daily administration of 50 
mg.kg-1 of d4T resulted in mechanical hyperalgesia in the rat tail within 3 weeks of 
drug administration. Lack of hyperalgesia in our study may be either due to 
differences in the two anatomical sites of nociceptive testing or differences in the 
techniques used to test for hyperalgesia. Weber and colleagues used a static, blunt 
stimulus applied to the tail whereas I used a dynamic blunt and punctate stimuli 
applied to the gastrocnemeus muscle. Also, antiretroviral toxic neuropathy is a 
length-dependent neuropathy, therefore by measuring hyperalgesia at the 
gastrocnemeus level and taking the sciatic nerve biopsies at the level of the thigh, 
rather than mid-way down the tail, I could have missed the hyperalgesia and nerve 
pathology. 
 
Although the oral bioavailability of d4T is complete in rats, with 100% of the oral 
dose reaching the systemic circulation (Kaul et al., 1999), our rats did not develop 
mechanical hyperalgesia. However, by administering the drug parenterally rather 
than orally, first-pass metabolism of the absorbed drug is bypassed, which may 
increase toxicity (Kaul et al., 1999). And only high doses of ddI administered for 
prolonged periods of time, orally administered d4T have not been shown to 
induce peripheral nerve damage in animal models of NRTI-induced neuropathy. 
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Therefore, in this study, I chose to use a higher dose of d4T (100mg.kg
-1
), 
administered subcutaneously, measured behavioral responses to a puctate stimulus 
in the tail and took biopsies from the tail. 
 
4.2 Methods 
The animal husbandry, nociceptive testing techniques, nerve processing, and data 
analyses used in this experiment are described in Chapter 2. 
 
Experimental procedures 
Twenty rats were randomly allocated to one of two groups; 10 rats were allocated 
to the control group and 10 rats to the d4T group. The rats were familiarized with 
the restrainers for three hours per day for a week before any experimental 
procedures were done. Baseline behavioral measurements were taken daily for 
five consecutive days before injections. Thereafter, the rats were injected with 100 
mg.kg
-1
 d4T or 1 ml.kg
-1
 saline subcutaneously daily for 28 days and behavioral 
measurements were carried out weekly over the treatment period. At the end of 
the period of drug administration, rats were anaesthetized using ketamine 
(Anaket-V; Bayer Animal Health Pty Ltd, Isando, South Africa) and xylazine 
(Chanazine; Bayer Animal Health Pty Ltd, Isando, South Africa) and the 
coccxygeal nerve was dissected free of the surrounding tissue ~20mm distal to the 
base of the tail, excised and placed in fixing solution. Thereafter animals were 
administered a lethal overdose of the anaesthetic. Nerve tissue also was collected 
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from an additional group of age-matched rats (n=5), which had not received any 
treatment nor had had behavioural measurements made on them.  
 
Drugs and method of administration 
In this study, 2’, 3’-didehydro-3’-deoxythymidine (d4T, Aspen Pharmacare, South 
Africa) was suspended in sterile isotonic saline (0.9%) immediately before 
injections, at a concentration of 100 mg.ml
-1
. Depending on their assigned group, 
animals were administered either 100 mg.kg
-1
 d4T or an equivalent volume of the 
saline subcutaneously daily. 
 
4.3 Results 
Behavioural nociceptive tests 
Figure 7 shows changes in the tail withdrawal thresholds to a punctate mechanical 
stimulus. The changes in withdrawal threshold over time were best described 
using second-order polynomial regression equations (Control: r
2
= 0.45, 
Sy.x=20.46; d4T: r
2
= 0.60, Sy.x=7.48). But the equations were not good fits for 
the data so these data were analyzed using the Student t-test to assess whether 
there was a difference in the tail withdrawal thresholds between the d4T and 
saline groups. The analysis was performed on the behavioral data collected at the 
end of each 7-day period (baseline, week 1, week 2, week 3, week 4), and we 
found that there is no significance difference in the withdrawal thresholds between 
the experimental and control animals at each time period. That is, daily injections 
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of d4T (100 mg.kg
-1
)
 
did not produce mechanical hypersensitivity to a punctate 
mechanical stimuli applied to the tail. 
 
Nerve pathology 
Figure 8 shows the appearance of typical cross sections through the coccxygeal 
nerve of rats administered daily subcutaneous injections of d4T (100 mg.kg
-1
) 
(Figure 8B) or an equivalent volume of saline (Figure 8A) over a four week 
period. There was no difference in the total number of myelinated axons (Figure 
9A; one-way ANOVA; p>0.05) or percentage of abnormal axons (e.g. myelin 
splitting) (Figure 9B; one-way ANOVA; p=0.38) between the no intervention, the 
salineand the d4T groups. Furthermore, daily subcutaneous administration of d4T 
(100 mg.kg
-1
)
 
did not alter the axoplasm area per axon (Figure 10A; one-way 
ANOVA; p=0.06) nor the myelin area per axon (Figure 10B; one-way ANOVA; 
p=0.12) compared to the no intervention and salinegroups. Thus, at the drug dose 
we used, d4T did not induce any significant nerve pathology. 
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Figure 7. Mean tail withdrawal thresholds in response to punctate mechanical 
stimulation with an electronic von Frey device measured in rats before (week 0) 
and during (weeks 1 to 4) four weeks of daily subcutaneous administration of 100 
mg.kg
-1
 d4T (diamonds) or an equivalent volume of saline (squares). There was 
no difference in the withdrawal threshold of the d4T group and control group over 
the four-week course of the experiment. 
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Figure 8. Cross-sections of the coccyxgeal nerve from animals administered 1 
ml.kg
-1
 saline (A) and 100 mg.kg
-1
 d4T (B) injections (40X magnification). No 
significant myelinated axon loss or fibre pathology was observed in rats 
administered d4T. The arrows show infolding and balooning of the myelin sheath.  
A 
B 
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Figure 9. The total number of axons (A) and percentage of abnormal axons (B) 
(i.e. ballooning, splitting of myelin sheath) per photo (10 000 µm
2
). Values are 
expressed as mean (SD). d4T (100 mg.kg
-1
) administration does not alter the 
number of axons or number of abnormal axons compared with the saline and 
naive groups (P>0.05). 
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Figure 10. Axopalsmic area per 10 000 µm
2
 (A) and myelin area per 10 000 µm
2
 
(B). Values are expressed as mean (SD). D4T (100 mg.kg-1) administration did 
not alter the axoplasmic area per cell or myelin area per cell compared to the 
saline and naive rats (P>0.05). 
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4.4 Discussion 
 
The aim of this experiment was to determine whether administering d4T 
subcutaneously to rats for four weeks causes hypernociception and 
neuropathological changes in nerve morphology. Daily injections of d4T at 100 
mg.kg
-1 
over a four week period did not induce the development of any 
neuromorphological pathology in myelinated fibres in the coccxygeal nerve. Also, 
the absence of this nerve fibre pathology correlated with the absence of 
hyperalgesia in our rats. Our study demonstrates that multiple injections of d4T at 
100 mg.kg
-1 
over a four week period do not induce nerve fibre pathology or 
hyperalgesia in rats.  
 
In our study, semi-thin sections of the coccxygeal nerves of rats administered d4T 
did not show changes associated with antiretroviral toxic neuropathy. On the other 
hand, Bhangoo and colleagues found that a single injection of ddC (25mg.kg
-1
) 
resulted in neuropathological changes in the peripheral nerves as early as post-
injection day 3, and these changes were present for about 48 days (Bhangoo et al., 
2007). Bhangoo and colleagues observed changes such as hypermyelination 
(tormaculae formation) in sciatic. Interestingly, in their model, a single 
intraperitoneal injection of ddC (25mg.kg
-1
)
 
produced mechanical hyperalgesia 
post-injection, as demonstrated by a significant decrease in paw withdrawal 
threshold from as early as post-injection day 3 (Bhangoo et al., 2007). The 
A 
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mechanical hypersensitivity produced by ddC administration was evident between 
weeks two to four post-injections and was sustainable for up to 43 days post initial 
exposure (Bhangoo et al., 2007). These findings are in agreement with those of 
Joseph and colleagues (2004) who administered three single intravenous doses 
(i.e. 10, 25 or 50 mg.kg
-1
)
 
of ddC, ddI and d4T to three different groups of rats and 
found that a single dose of these drugs resulted in a significant reduction to paw-
withdrawal threshold as early as post-injection day 1 for rats administered 50 
mg.kg
-1
 or day 3 for rats administered 10 and 25 mg.kg
-1 
of these drugs.  
 
Although other researchers have been able to successfully develop models of 
NRTI toxicity and hyperalgesia, most of them have used NRTIs that have greater 
neurotoxicity than d4T, ddC and ddI, which are no longer used as first-line 
management of HIV infection. Patients with HIV-SN have evidence of dying back 
sensory axonal degeneration, with the most distal portions of long fibers being 
affected first. Keswani and colleagues (2003b) developed a model of HIV 
neuropathy using GFAP-gp120 transgenic mice, which expressed a viral coat 
protein gp120 in all tissues, and these mice were administered ddI (25mg.d-1) for 
four weeks. Mice developed hypernociception, but proximal sciatic nerve sections 
obtained from the wild-type and gp120 transgenic mice with and without 
exposure to ddI did not show any evidence of Wallerian-like degeneration and 
there were no changes noted in the morphology of myelinated axons (Keswani et 
al., 2006). Moreover, Wallace et al (2007) found no evidence of neural stress 
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marker ATF-3, a marker that is increased, following neuronal damage, in the 
dorsal root ganglia neurons in rats administered 50 mg/kg
-1
 ddC intraperitoneally 
and had developed hypernociception. Thus, development of hypernociception 
following NRTI administration does not necessarily mean that there will be overt 
axonal pathology. 
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CHAPTER 5 
 
Conclusion 
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Stavudine (d4T), an NRTI often used as first-line treatment for HIV infection, is 
associated with peripheral neuropathy and pain in HIV-positive patients (Wadley 
et al., 2011; Maritz et al., 2010). The mechanisms of d4T-induced toxic 
neuropathy and pain are not well understood, partly because of a lack of robust 
animal models of the disease process. To date, very few studies have examined 
the effects of d4T on peripheral nerves and the associated hyperalgesia in animals. 
Instead most researchers have focused their attention on the more toxic NRTI 
ddC, which is no longer prescribed for HIV management. Therefore, the primary 
aim of my dissertation was to investigate whether acute daily oral or subcutaneous 
administration of d4T produces neuropathological changes associated with the 
administration of NRTIs.  
 
Daily oral administration of d4T at 50 mg.kg
-1 
over a four week period did not 
induce significant nerve fibre loss or morphological changes in myelinated fibres 
in the sciatic nerve. Congruent with the absence of neurotoxicity, daily 
administration of d4T at a dose of 50 mg.kg
-1
over a four week period did not 
result in hyperalgesia. The behavioral data are contrary to the results of Weber et 
al (2007) who observed mechanical hyperalgesia in rats within three weeks, 
following daily oral administration of 50 mg.kg-1 d4T. In the second experiment, I 
investigated whether administering 100 mg.kg
-1 
d4T subcutaneously to rats for 
four weeks caused neuropathological changes in myelinated fibres in the 
coccxygeal nerve. As with the lower dose of d4T, d4T at a dose of 100 mg.kg
-1 
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over a four week period, did not induce neuronal loss or myelin abnormalities. 
And, the absence of this nerve fibre pathology correlated with the absence of 
hyperalgesia in our rats. Based on these findings, it appears that developing a 
robust animal model of d4T-induced neuropathy may be challenging in the 
absence of underlying HIV-infection, and may require exposure to d4T for a 
longer period or higher doses than what I studied.  
 
 Failure to develop a model of d4T-induced neuropathy in otherwise healthy rats 
in our study is not surprising, since this has seldom been achieved successfully. 
Previously in our laboratory, Weber et al (2007) demonstrated that hyperalgesia to 
a mechanical stimulus developed within three weeks of daily oral d4T 
administration, something I failed to repeat in my series of studies. But they did 
not determine whether the hyperalgesia was caused by peripheral nerve damage, 
so it is unclear whether the hyperalgesia was indeed neuropathic in origin. Indeed 
they found no changes in dorsal horn apoptosis, a feature of neuropathic pain 
states, so it is unlikely that the hyperalgesia was neuropathic in origin (Weber et 
al., 2009). Furthermore, in a study done by Warner and colleagues (1995), there 
were no drug-induced light or electron microscopic changes in the peripheral 
nerves of rabbits treated with ddI, d4T or AZT for 24 weeks. In another study, 
ddC produced peripheral neuropathy in cynomolgus monkeys at doses ranging 
between 0.2-10mg.kg-1 body weight twice daily for up to 38 weeks (Anderson et 
al., 1992); but, d4T failed to produce any evidence of neuropathy in cynomologus 
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monkeys at doses of 60, 200 or 5600 mg.kg
-1
 body weight per day over a 1 year 
period (Warner et al., unpublished data). Thus, even if greater doses of d4T are 
used, or the drug is used for a longer period of time than the four weeks I 
administered the drug, I believe that peripheral nerve damage and 
hypernociception may still not be produced in rats. If the neurotoxicity of d4T is 
low when administered to experimental animals, how is it that the drug is so 
strongly associated with HIV-SN in patients being treated with the drug. The most 
likely reason for greater toxicity in patients is that patients have underlying nerve 
damage caused by the virus infection (Kokotis et al., 2007; Keswani et al., 2002), 
making them more susceptible to the additional neurotoxic load of d4T than 
healthy rodents. 
 
In South Africa, there are two recommended treatment therapies which contain at 
least 2 NRTIs and either a NNRTI or PI. Until recently, the first and second line 
treatment therapies included d4T and ddI respectively (National Antiretroviral 
Treatment Guideline, first edition, 2004), which are potent NRTI and are 
associated with ATN. Although the guidelines have been amended, such that new 
patients starting therapy do not start on d4T or ddI base regimens; however, the 
bulk of existing patients remain being treated with these drugs.  
 
Currently, the mechanisms of antiretroviral toxic (ATN) neuropathy are not fully 
understood as it is difficult to develop a model of NRTI without HIV infection or 
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exposure to Human Immunodeficiency Virus–glycoprotein 120 (HIV-gp120) in in 
vivo rodent models of HIV-SN. In a model of ddC-induced HIV-gp120 induced 
nerve damage and hypernociception, Wallace and colleagues (2007) demonstrated 
that perineural administration of HIV-gp120 sensitizes rats to the static punctate 
mechanical stimulus. HIV infection is associated with an increased amount of 
circulating activated macrophages and pro-inflammatory cytokines (Keswani et 
al., 2002). These enter the dorsal root ganglion (DRG) and peripheral nerves in 
large numbers and upon entering the DRG, they release chemokines and cytokines 
which promote neurotoxicity (Keswani et al., 2002; Keswani et al., 2003a). Also, 
within the DRG, some of the secreted viral proteins (e.g. Tat, gp120) are thought 
to be toxic to DRG neurons, thus resulting in a “dying back” pattern of axonal 
degeneration (Keswani et al., 2002). Some researchers have hypothesized that the 
development of antiretroviral toxic neuropathy (ATN) is due to the “unmasking” 
of clinically silent pre-existing neuronal damage due to HIV (Kokotis et al., 2007; 
Keswani et al., 2002). In another model, Laast and colleagues (2007) inoculated 
macaques with Simian Immunodeficiency Virus (SIV) in order to better 
understand the immunological responses associated with HIV infection and the 
signaling process that ultimately produces symptomatic HIV-SN. In their model, 
they observed a significant decrease in neuronal density within the trigeminal 
nerve, which was inversely proportional to macrophage infiltration that seemed to 
suggest that macrophage infiltration plays a key role in causing nerve damage in 
HIV infected patients (Laast et al., 2007; Laast et al., 2011). It is likely that there 
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is a concomitant need for HIV infection as well as abnormalities in the peripheral 
nervous system that are requirements for the development of ATN (Keswani et 
al., 2002).  
 
Thus, while developing models of d4T is academically interesting, and would 
provide a way to better understand the neurotoxicity of the drug as such, the drug 
is typically used in individuals infected with HIV, except in cases of post-
exposure prophylaxis. Therefore any attempt to better understand the 
pathophysiology of ATN induced by d4T should in the future be based around 
models employing simulated HIV infection. For example, administering d4T to 
transgenic mice expressing constitutive gp120, monkeys or cats infected with SIV 
or FIV respectively, or rodents exposed to exogenous gp120. Only through such 
models will be able to learn about the true mechanisms underlying d4T-induced 
ATN. And, I believe that we need to continue investigating the mechanisms of 
this neuropathy, despite new regulations removing d4T as a first-line treatment 
(DOH, 2010), because the majority of South Africans, and the majority of 
individuals in other developing countries, who are receiving treatment have been 
exposed to d4T, and any exposure to the drug increases the risk of developing 
ATN (Cherry et al., 2010). Despite the change in first-line treatment regimen, 
there remains a high risk for continued high rates of d4T-related ATN going 
forward. Also, only by determining the underlying mechanisms of d4T- related 
ATN will we possibly identify possible therapeutic targets for the treatment of the 
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painful symptoms of this neuropathy, which has remained resistant to standard 
therapies for painful polyneuropathies (Phillips et al., 2010)  
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